Irbesartan

6 trials 1 recruiting CCardiology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

4 Completed trials

5 Sponsors

14 Countries

Phase III

Phase IV

Phase III: 4 Phase IV: 2

Indications tested

Focal segmental glomerulosclerosis 2 Acute kidney injury 1 IgA nephropathy 1

Sponsors using this IMP

Travere Therapeutics Inc. 2 Assistance Publique Hopitaux De Paris 1 Dimerix Bioscience Pty Limited 1 Institute For Study Research Education And Therapy Of Vascular Heart Brain And Kidney Nosologies 1 Policlinico San Donato S.p.A. 1

All trials

6 total

Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEB… Pending

2024-519749-31-00 Phase IV 1 country Institute For Study Research Education And Therapy Of Vascular Heart Brain And K…
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting

2025-520660-18-00 Phase IV 1 country Policlinico San Donato S.p.A.
Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N… Ended

2024-515845-40-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Phase III 7 countries Dimerix Bioscience Pty Limited
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Phase III 11 countries Travere Therapeutics Inc.
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Phase III 12 countries Travere Therapeutics Inc.

Showing 1–6 of 6 trials

← All drugs A–Z